Value
4.8/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 5.3 |
| P/S | 6.1 |
| EV/EBITDA | 1.8 |
| Fwd P/E | 6.8 |
| PEG | 5.6 |
| Analyst target | 3.0 |
- ▸Forward P/E: 18.9x
- ▸PEG: 1.34
RMD · Why this verdict
Why ResMed (RMD) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score5.5/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
ResMed is a wide-moat medical devices company with a perfect Piotroski F-Score of 9 out of 9, 25% return on equity, and four consecutive earnings beats, currently experiencing a technical downtrend that creates an accumulation opportunity for investors with a 12-to-18 month horizon.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
ResMed scores 9.2 out of 10 on quality with a wide economic moat, 25% return on equity, 27% net margins, and a perfect Piotroski F-Score of 9 out of 9, placing it in the top tier of all healthcare companies evaluated on fundamental business strength. Quality breakdown | Return on equity remains above 20% and net margins stay above 24% over the next four quarters, confirming the moat is holding despite competitive pressure from connected device alternatives. | →Stable |
| CounterThe premium valuation implied by a forward price-to-earnings of 15.9 times leaves little cushion if GLP-1 weight-loss drugs reduce the obstructive sleep apnea patient population by reducing obesity-related incidence. | ||
ResMed has beaten earnings estimates in each of the last four consecutive quarters with an average positive surprise of 2.53%, demonstrating consistent delivery against consensus expectations even in a challenging competitive environment. Earnings | The beat streak extends to six or more consecutive quarters as device adoption in undiagnosed sleep apnea populations grows and software subscription revenue scales. | →Stable |
| CounterAn average surprise of only 2.53% is a thin margin; modest estimation revisions could easily convert to misses, particularly if GLP-1 drug adoption accelerates faster than management anticipates. | ||
The stock is in a confirmed downtrend with the 200-day moving average slope at -4.5% over 30 days and falling on-balance volume, but analyst consensus sees 40% upside to targets, creating a divergence between price action and fundamental valuation. Momentum breakdown | Price reclaims the 200-day moving average within 12 months and the entry target of $188.81 is reached, beginning a move toward the analyst consensus target near $243. | ↓Deteriorating |
| CounterDowntrends in medical device companies can persist for extended periods when driven by secular concerns like GLP-1 disruption; catching a falling knife often requires a specific positive catalyst rather than just waiting for mean reversion. | ||
The analyst consensus price target implies 40% upside from the current $192.74, ranking the analyst upside score at 9.2 out of 10, while the forward price-to-earnings multiple of 15.9 times is attractively valued for a wide-moat healthcare compounder. Sentiment breakdown | The stock reaches at least $240 within 12 months as the technical downtrend reverses and the market re-rates the company on its fundamental quality. | ↓Deteriorating |
| CounterAnalyst price targets lag significantly in their response to new structural threats; the 40% upside may reflect targets set before the full impact of GLP-1 disruption was understood, and upgrades may be slow to materialize. | ||
ResMed scores 9.2 out of 10 on quality with a wide economic moat, 25% return on equity, 27% net margins, and a perfect Piotroski F-Score of 9 out of 9, placing it in the top tier of all healthcare companies evaluated on fundamental business strength.
→StableQuality breakdown
- Expectation
- Return on equity remains above 20% and net margins stay above 24% over the next four quarters, confirming the moat is holding despite competitive pressure from connected device alternatives.
CounterThe premium valuation implied by a forward price-to-earnings of 15.9 times leaves little cushion if GLP-1 weight-loss drugs reduce the obstructive sleep apnea patient population by reducing obesity-related incidence.
ResMed has beaten earnings estimates in each of the last four consecutive quarters with an average positive surprise of 2.53%, demonstrating consistent delivery against consensus expectations even in a challenging competitive environment.
→StableEarnings
- Expectation
- The beat streak extends to six or more consecutive quarters as device adoption in undiagnosed sleep apnea populations grows and software subscription revenue scales.
CounterAn average surprise of only 2.53% is a thin margin; modest estimation revisions could easily convert to misses, particularly if GLP-1 drug adoption accelerates faster than management anticipates.
The stock is in a confirmed downtrend with the 200-day moving average slope at -4.5% over 30 days and falling on-balance volume, but analyst consensus sees 40% upside to targets, creating a divergence between price action and fundamental valuation.
↓DeterioratingMomentum breakdown
- Expectation
- Price reclaims the 200-day moving average within 12 months and the entry target of $188.81 is reached, beginning a move toward the analyst consensus target near $243.
CounterDowntrends in medical device companies can persist for extended periods when driven by secular concerns like GLP-1 disruption; catching a falling knife often requires a specific positive catalyst rather than just waiting for mean reversion.
The analyst consensus price target implies 40% upside from the current $192.74, ranking the analyst upside score at 9.2 out of 10, while the forward price-to-earnings multiple of 15.9 times is attractively valued for a wide-moat healthcare compounder.
↓DeterioratingSentiment breakdown
- Expectation
- The stock reaches at least $240 within 12 months as the technical downtrend reverses and the market re-rates the company on its fundamental quality.
CounterAnalyst price targets lag significantly in their response to new structural threats; the 40% upside may reflect targets set before the full impact of GLP-1 disruption was understood, and upgrades may be slow to materialize.
Per-dimension breakdown
Quality
8.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 8.1 |
| ROA | 9.3 |
| Gross margin | 8.3 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 9.9 |
| FCF quality | 4.8 |
| Moat | 8.4 |
| Piotroski F | 10.0 |
- ▸Strong margins: 27%
- ▸Earnings quality warning: 62% FCF/NI
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
Growth
3.5/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 4.6 |
| EPS growth | 2.5 |
Momentum
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.9 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 7.5 |
| Volume | 0.0 |
- ▸Overbought (RSI 82)
- ▸Volume distribution (falling OBV)
- ▸Above 200-MA but MA slope flat/negative + RSI 82 (late-cycle distribution risk)
Sentiment
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.5 |
| Analyst rating | 7.4 |
| Price target | 4.9 |
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.0 |
- ▸Insider selling (low materiality) — $5,396,112 (0.015% of mkt cap)
Peer rank
6.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.6 |
| quality rank | 9.5 |
| growth rank | 4.3 |
- ▸Superior ROE vs peers
- ▸Best-in-class margins
Technical
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.9 |
| support resistance | 0.7 |
| 52w position | 8.0 |
| gap | 5.0 |
Risk (lower is worse)
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.7 |
| days to cover | 0.0 |
| volatility | 7.0 |
| put call | 2.9 |
| implied vol | 5.2 |
| max pain risk | 3.0 |
| beta | 8.5 |
| debt equity | 9.5 |
- ▸Elevated put/call: 1.57
- ▸Above max pain $155
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 3.7 |
| dividend safety | 8.5 |
| news activity | 6.0 |
- ▸Perfect beat streak: 4Q
- ▸Earnings today
- ▸Dividend aristocrat: 1.1% yield
How the verdict was assembled
Engine trigger
Earnings today. Wait until post-earnings.
Engine technical detail
verdict_path:
L3:NEWS_BLOCK|ENTRY_STICKY:WITHIN_BANDPassed (4)
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (4)
- MOMENTUM:4.5<4.5
- ASYMMETRY:-0.8=NEGATIVE
- 8K_CRITICAL:4.01
- EARNINGS_PROXIMITY:0d<=7d
Warning (0)
none
Reward-to-Risk
-0.76
Upside
-10.6%
Downside
13.9%
Sizing output
STARTER
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityModerate — Balanced profile
Investment implication
A recent news event triggered an L3 news-block on the verdict path. Trigger: Earnings today. Wait until post-earnings. The 10-dimension scores remain Quality at 8.8 (strongest), but MOMENTUM:4.5<4.5 also fails — the news block is the proximate trigger, not the sole driver.
The strongest dimensions are Quality at 8.8, Peer rank at 6.4, and Catalyst at 6.4; the weakest are Growth at 3.5, Technical at 3.9, and Momentum at 4.5. The V9 engine flagged 4 failed gates, producing an asymmetric reward-to-risk of -0.76 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Wide Moat Compounder Quality
Trip ifReturn on equity falls below 18% for 2 consecutive quarters, signaling the competitive moat is weakening under margin pressure.
- P2Perfect Earnings Beat Streak
Trip ifEPS surprise falls below 0% in at least 2 of the next 4 quarters, ending the sustained beat pattern.
- P3Technical Downtrend Accumulation Window
Trip ifPrice drops below $170, more than 12% below the current $192.74, confirming the downtrend is deepening rather than stabilizing.
- P4Analyst Upside Valuation Gap
Trip ifAnalyst consensus price target falls below $200, indicating analysts are cutting their fair value estimates by more than 20% from current levels.